Back

Two medical oncologists recording at the 2026 World Conference on Lung Cancer (WCLC) in Seoul use new evidence as a way into 2 biomarkers in non-small cell lung cancer (NSCLC). The program covers what EGFR and KRAS G12C results tell a clinician beyond treatment selection, the EGFR result at progression and the updated HARMONi overall survival analysis, AMIGO-1 and COPERNICUS data, EGFR and central nervous system disease, KRAS G12C in practice and neoadjuvant NAUTIKA1 data, broad molecular profiling from diagnosis, and closing clinical pearls.

2026 WCLC Through a Biomarker Lens The Biomarker Behind the Data: EGFR and KRAS G12C

Episodes

Specialty:

All

Year:

All

EP. 1: What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

ByEric K. Singhi, MD,Misty D. Shields, MD, PhD

September 24th 2026

New WCLC insights show how EGFR and KRAS G12C biomarkers shape lung cancer biology, resistance, prognosis, and smarter testing for personalized care.

2026 WCLC Through a Biomarker Lens The Biomarker Behind the Data: EGFR and KRAS G12C

Episodes

EP. 1: What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma